ERCC1 Expression and Outcomes in Head and Neck Cancer Treated with Concurrent Cisplatin and Radiation

Overexpression of excision repair cross complementing group 1 (ERCC1), a DNA repair enzyme, is associated with resistance to cisplatin. Tissues from 73 patients with squamous cell carcinoma of the head and neck (HNSCC) who received concurrent cisplatin and radiation was analyzed immunohistochemicall...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2011-12, Vol.31 (12), p.4135-4139
Main Authors: HAYES, Mose, LAN, Cynthia, JINGSHENG YAN, YANG XIE, GRAY, Toby, AMIRKHAN, Robin H, DOWELL, Jonathan E
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - pharmacology
Biological and medical sciences
Cisplatin - therapeutic use
Combined Modality Therapy - methods
DNA Repair
DNA-Binding Proteins - biosynthesis
Endonucleases - biosynthesis
Gene Expression Regulation, Neoplastic
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - metabolism
Head and Neck Neoplasms - radiotherapy
Humans
Immunohistochemistry - methods
Medical sciences
Middle Aged
Otorhinolaryngology (head neck, general aspects and miscellaneous)
Otorhinolaryngology. Stomatology
Radiotherapy - methods
Retrospective Studies
Treatment Outcome
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Overexpression of excision repair cross complementing group 1 (ERCC1), a DNA repair enzyme, is associated with resistance to cisplatin. Tissues from 73 patients with squamous cell carcinoma of the head and neck (HNSCC) who received concurrent cisplatin and radiation was analyzed immunohistochemically to determine if ERCC1 expression predicted for survival and response. Expression was scored as follows: 0=0% tumor nuclei positive, 1+=75%. ERCC1 expression was 0 in 0%, 1+ (14%), 2+ (42%) and 3+ (44%). In uni- and multivariate analyses, 3+ ERCC1 expression was not a significant predictor of survival or response. Median survival for the ERCC1 3+ patients was 2.9 years versus 2.1 years for the ERCC1
ISSN:0250-7005
1791-7530